Basic Information of Clascoterone
- Product Name:Clascoterone
- Chemical Name:cortexolone 17α-propionate
- IUPAC Name：17α-propionyloxy-3β-hydroxyandrosta-3,5-dien-3-one (alternative)
- CAS No.:19608-29-8
- Molecular Formula:C₂₄H₃₄O₅
- Molecular Weight:402.52 g/mol
- Appearance:White to off-white powder
Applications of Clascoterone
- Clascoterone (1% Cream) for the treatment of acne;
- Clascoterone (5% Topical Solution) for the treatment of hair loss;
- Clascoterone API serves as a reference standard for analytical method development, method validation, quality control, and related applications.
Attention: The Clascoterone powder we supply is intended for research purposes only.
Why choose Highassay?
Highassay is a China-based supplier of Clascoterone raw materials; we provide high-purity Clascoterone powder for use in the research and development of finished Clascoterone drug products.
We employ advanced manufacturing processes for Clascoterone API, ensuring high purity (≥98%), a well-defined and controllable impurity profile, and stable crystalline form.Consistent data across batches can help you complete your R&D preparations ahead of time while remaining compliant with regulations.Provides assurance for rapidly capturing the market following patent expiration.
We will provide a COA, XRPD spectrum, impurity profile analysis, and accelerated stability study data along with the shipment, helping you save 3 to 6 months of early-stage R&D time.
Buy Clascoterone,choose Highassay.
Information Overview
- Specification of Clascoterone
- Physicochemical Properties of Clascoterone
- Safety and Packaging of Clascoterone
| Item | Standard | Test Method |
| Purity | ≥98%（customized≥99%） | HPLC |
| Single Impurity | ≤0.5% | HPLC |
| Total Impurities | ≤1.0% | HPLC |
| Loss on Drying | ≤0.5% | 105℃Constant-Temperature Drying Method |
| Heavy Metals | ≤10 ppm | Atomic Absorption Method |
| Residual Solvents | Meet ICH Q3C | GC |
| Microbial Limits | Compliant with USP/EP | Pharmacopoeia Method |
| Standards Complied | USP/EP/CP/GMP | Pharmacopoeia Standards |
| Item | Details |
| Melting Point | ~152–156 °C |
| Solubility | Soluble in DMSO, ethanol; slightly soluble in water |
| LogP (XlogP) | 3.9 |
| TPSA | 80.7 Ų |
| Stability | Sensitive to light, heat, and humidity |
| Storage Conditions | 2–8℃, sealed, dry, avoid light |
| Item | Details |
| GHS Classification | Not classified as hazardous |
| Hazard Statements | No hazard statements |
| Packaging | ≤100mg(Vial)；≤1kg(Aluminum Foil Bag) |
| Transport Conditions | Transport at room temperature; avoid direct sunlight, moisture, and severe impact. |
Clascoterone Definition and Mechanism of Action
Clascoterone API is a First-in-Class Topical Antiandrogen for Acne & Alopecia.By competitively binding to AR in the skin, it blocks DHT-driven excessive sebum secretion and inflammation.It offers targeted solutions for acne vulgaris and also demonstrates positive and effective results in the field of AGA.
Clascoterone vs. Spironolactone vs. Finasteride
Clascoterone is a topical preparation, whereas spironolactone and finasteride are oral preparations; this constitutes the primary difference between them.
Oral formulations of spironolactone and finasteride primarily exert systemic effects; while they offer greater efficacy, they also carry higher risks and side effects.
Unlike systemic antiandrogens, Clascoterone is applied topically and does not enter the bloodstream, thereby significantly reducing the likelihood of hormone-related side effects.
| Comparison Item | Clascoterone | Spironolactone | Finasteride |
| Target | Androgen receptor (AR) antagonist | Androgen receptor antagonist + diuretic | Type II 5α-reductase inhibitor |
| Mechanism of Action | Competitively binds to AR, blocks DHT signaling | Blocks AR + inhibits testosterone synthesis | Inhibits conversion of testosterone to DHT |
| Administration | Topical (cream / solution) | Oral (tablets) | Oral (tablets) or topical |
| FDA-Approved Indications | Acne (12 years+) | Acne, hypertension, heart failure (off-label for alopecia) | Androgenetic alopecia (males), benign prostatic hyperplasia |
| Status for Alopecia | Phase III (5% solution) with positive results | Off-label use (mainly in females) | FDA-approved (males) |
| Systemic Exposure | <1% (soft drug design) | 100% (systemic distribution) | 100% (oral administration) |
| Sex Hormone-Related Side Effects | None (not observed in clinical trials) | Menstrual irregularities, breast tenderness, decreased libido | Erectile dysfunction, decreased libido, gynecomastia |
| Suitability for Males | Safe | Generally not recommended for males (feminizing effects) | For males only |
| Suitability for Females | Safe | Commonly used | Contraindicated (risk of teratogenicity) |
The MOQ is ≥ 5 mg. We offer flexible order quantities; please feel free to inform us directly of your specific requirements. However, please note that the price of the Clascoterone API may vary depending on your purchase volume. Contact us, and we will respond within 24 hours with our latest product quotation.
Yes, we provide these documents upon request. If you require them, please contact our customer service team.
19608-29-8.
